Canadian Urological Association (CUA)

In this podcast, Dr. Aly-Khan Lalani and Dr. Peter Black discuss the latest advancements in treatment for patients with muscle-invasive bladder cancer, the clinical efficacy of newly available treatment options in Canada, and treatment selection and management considerations for treatment regimens in Canada.

Episode NotesPodcast Host Disclosures: Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria from: Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura. Committees: NCCN, GU Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. Medical writing and editorial assistance support may have been funded by Communications companies in part. No speaker’s bureau. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI.  Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst). Accreditation: This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

The fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer. Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com References from the show: Bladder Cancer Canada Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

The third episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez/Munoz. This episode features a discussion on urinary tract infections in women. Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

The second episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez/Munoz. This episode features a discussion on male voiding disorders and Benign Prostatic Hyperplasia (BPH). Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com References from the show: CUA BPH Guidelines - Google Search Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)   Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Do you have questions or a suggestion for a future topic? Email our hosts: 2peesinapodpodcast@gmail.com References from the show: UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis - PMC (nih.gov) UBC & VGH Centre of Excellence | Vancouver Prostate Centre Welcome to Canadian Urological Association | Canadian Urological Association (cua.org)   Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Program Chair: Ricardo Rendon Kidney Cancer Panelists: Melissa Huynh, Lori Wood   Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

Program Chair: Ricardo Rendon Kidney Cancer Panelists: Melissa Huynh, Lori Wood   Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

Program Chair: Ricardo Rendon Bladder Cancer Panelists: Peter Black, Maria Jiang   Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

Program Chair: Ricardo Rendon Bladder Cancer Panelists: Peter Black, Maria Jiang   Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

Program Chair: Ricardo Rendon Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan   Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

Program Chair: Ricardo Rendon Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan   Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen

Fred Saad, MD, FRCS CHUM, Institut de cancer de Montreal/CRCHUM

Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP University of Montreal Institut de cardiologie de Montreal

Darryl Leong, MD McMaster University

Fred Saad, MD, FRCS CHUM, Institut de cancer de Montreal/CRCHUM

Jean Gregoire, MD, FRCP(C), FCCS, FACC, FACP University of Montreal Institut de cardiologie de Montreal

Sponsored by Amgen. Luke Lavallee Urologic Oncologist and Associate Scientist The Ottawa Hospital Ottawa Hospital Research Institute Disclosures: Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas Grant/Honorarium: Sanofi

Sponsored by Amgen. Sophie Mottard Orthopedic Oncology Surgeon Maisonneuve-Rosemont Hospital CHU Saint-Justine and Santa Cabrini Hospital Disclosures: Payment: Amgen (conference speaker)

Sponsored by Amgen. David Kendler Endocrinologist and Clinical Professor UBC Disclosures: Advisory Board: Amgen, Paladin, Biosynt Speakers Bureau: Amgen Payment: Amgen, Biosynt, Radius Pharma, Paladin Grant/Honorarium: Amgen, Biosynt, Radius Pharma, Paladin Clinical Trial: Radius Pharma Leadership/Board Position: Specialists of BC, Drs. of BC section of Endocrinology (executive)